Finally, we performed a systematic multi-omics analysis of ABCA1 in STAD, and the results demonstrated that ABCA1 can predict outcomes in patients with STAD and has the potential to be a new therapeutic target for STAD. This evidence concerns the gene ABCA1 and gastric adenocarcinoma.